Phenergan

PreclinicalSmall molecule

Novartis

Phenergan is one of 40 small molecule programs targeting Nausea and vomiting. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Nausea and VomitingPreclinical

Active, not recruiting

Competition

Competitive Landscape

78 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

63 2

Zyprexa

MMODAG GmbH

Approved

16 3

Ketalar

AAultman Health Foundation

Approved

2 4

Thalomid

Bristol-Myers Squibb

Phase 3

2 5

Megace

Bristol-Myers Squibb

Phase 3

1 6

Abraxane

Bristol-Myers Squibb

Phase 3

1 7

Gemzar

Johnson & Johnson

Phase 3

1 8

Nereus

VVanda Pharmaceuticals

Phase 3

2 9

HSK21542

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

1 10

Adriamycin

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea1 trial

Prevention of Narcotic-Induced Nausea

Terminated·CChristiana Care Health Services·N/A·NCT00541671·25 enrolled

Fasting Conditions1 trial

To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00947063·36 enrolled

Treatment1 trial

A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions

Completed·CCharleston Laboratories, Inc·Phase 1·NCT02465866·20 enrolled

Nausea and vomiting1 trial

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

Completed·MM.D. Anderson Cancer Center·N/A·NCT02473042·188 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Phenergan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phenergan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phenergan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

Phenergan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea1 trial

Fasting Conditions1 trial

Treatment1 trial

Nausea and vomiting1 trial

References

Drug Info

Quick Facts

Related News